Adenoviral vector immunity: its implications and circumvention strategies.
Adenoviral vector immunity: its implications and circumvention strategies.
复制标题
DOI：
10.2174/156652311796150372
复制
发表时间：
2011-08
影响因子：
3.6
通讯作者：
Mittal SK
中科院分区：
文献类型：
--
作者：
Ahi YS;Bangari DS;Mittal SK
在过去的二十年中，腺病毒（Ad）载体已成为一种有前途的基因递送平台，可用于各种治疗和疫苗目的。然而，预先存在的Ad免疫的存在和Ad载体免疫的快速发展仍然对这些载体的临床使用提出了重大挑战。 Ad载体施用后的先天炎症反应可能导致全身毒性，极大地限制载体转导效率并显着缩短转基因表达的持续时间。目前，人们正在广泛寻求多种方法来通过针对宿主或Ad载体的策略来克服这些缺点。此外，基于不太流行的人类Ad血清型和非人类Ad的新型Ad载体的开发也取得了重大进展。这篇综述提供了我们目前对 Ad 载体免疫反应的最新理解，并描述了逃避 Ad 载体免疫的各种方法。根据其前景和局限性讨论了针对宿主的方法和针对载体的方法。
Adenoviral (Ad) vectors have emerged as a promising gene delivery platform for a variety of therapeutic and vaccine purposes during last two decades. However, the presence of preexisting Ad immunity and the rapid development of Ad vector immunity still pose significant challenges to the clinical use of these vectors. Innate inflammatory response following Ad vector administration may lead to systemic toxicity, drastically limit vector transduction efficiency and significantly abbreviate the duration of transgene expression. Currently, a number of approaches are being extensively pursued to overcome these drawbacks by strategies that target either the host or the Ad vector. In addition, significant progress has been made in the development of novel Ad vectors based on less prevalent human Ad serotypes and nonhuman Ad. This review provides an update on our current understanding of immune responses to Ad vectors and delineates various approaches for eluding Ad vector immunity. Approaches targeting the host and those targeting the vector are discussed in light of their promises and limitations.